Mitochondrial DNA Content as RiskFactorfor Bladder Cancer and its Association with Mitochondrial DNA Polymorphisms

Stephen B. Williams[1,2], **Yuanqing Ye**[1], **Maosheng Huang**[1], **David W. Chang**[1], **Ashish M. Kamat**[2], **Xia Pu**[1], **Colin P. Dinney**[2], and **Xifeng Wu**[1]

[1]Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX

[2]Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

Mitochondrial DNA (mtDNA) content has been shown to be associated with cancer susceptibility. We identified 926 bladder cancer patients and compared these to 926 healthy-controls frequency matched on age, gender, and ethnicity. Patients diagnosed with bladder cancer had significantly decreased mtDNA content when compared to control subjects (median: 0.98 vs. 1.04, p<0.001). Low mtDNA content (ie, less than the median in control subjects) was associated with a statistically significant increased risk of bladder cancer, when compared with high mtDNA content (Odds Ratio (OR) = 1.37, 95% CI = 1.13 to 1.66, p<0.001). In a trend analysis, a statistically significant dose–response relationship was detected between lower mtDNA content and increasing risk of bladder cancer (*P* for trend <0.001). When stratified by host characteristics, advanced age (>65 years), male/female sex and positive smoking history were all significantly associated with low mtDNA content and increased risk of bladder cancer. We identified two unique mtDNA polymorphisms significantly associated with risk of bladder cancer: mitot10464c (OR=1.39 95%CI: 1.00–1.93, p=0.048) and mitoa4918g (OR=1.40, 95% CI: 1.00–1.95, p=0.049). Analysis of the joint effect of low mtDNA content and unfavorable mtDNA polymorphisms revealed a 2.5 fold increased risk of bladder cancer (OR=2.50, 95% CI: 1.60–3.94, p<0.001). Significant interaction was observed between mitoa4918g and mtDNA content (p for interaction = 0.028). Low mtDNA content was associated with increased risk of bladder cancer and we identified new susceptibility mtDNA alleles associated with increased risk that require further investigation into the biological underpinnings of bladder carcinogenesis.

Keywords

Mitochondria; DNA; Risk; mtDNA content; Polymorphisms; Bladder Cancer

INTRODUCTION

There are an estimated 74,690 new cases and 15,580 deaths from bladder cancer in the United States projected in 2014 (1). Despite multimodality treatment strategies, oncologic outcomes have not improved resulting in an increased demand for enhanced early detection, patient selection and targeted therapeutic strategies (2). Although the mortality/incidence ratio is higher for bladder cancer than for prostate cancer, the comparatively low incidence in the general population has been an obstacle to the development of effective screening initiatives (3). Screening of well-defined high-risk populations with bladder cancer prevalence comparable to tumor entities accepted for screening (e.g. breast cancer or colorectal cancers) may offer a solution to this problem (3, 4).

Gender specific differences for bladder cancer diagnosis and prognosis have been well described with men being diagnosed more frequently (5). However, women tend to be diagnosed with more advanced disease which may translate into inferior oncologic outcomes (5, 6). Human mitochondrial DNA (mtDNA) is a maternally inherited genome consisting of a 16 569–base-pair circular double-stranded DNA molecule that encodes 13 polypeptides of the respiratory chain, 22 transfer RNAs, and 2 ribosomal RNAs (7). Each mitochondrion contains 2–10 mtDNA molecules with the number of mtDNA copies in a cell ranging from several hundred to more than 10,000 copies (7, 8). The mtDNA content varies per cell type from peripheral blood mononuclear cells having 223–854 copies (9) to neurons having 1200–10,800 mtDNA content per cell (10). Moreover, prior studies have reported a non-normal mtDNA content distribution of mtDNAs extracted from human peripheral leukocytes or whole blood (only leukocytes in whole blood contain mtDNA) (11, 12).

Normally, mtDNA content exists in a steady state related to tissue specific energy demand of the host cells (13). Variations of mtDNA content in cells among the general population have been reported (14). Moreover, mtDNA content appears to have high heritability (8) with a decrease in mtDNA content being associated with many types of cancers. We have previously published on the heritability and reliability of mtDNA content derived from peripheral blood lymphocytes as well as the association between decreased mtDNA content and increased risk of renal cell carcinoma (8), esophageal (15), and sarcoma (16) Other studies also reported similar association in ovarian(17), gastric(18), hepatocellular(19), and breast(20) cancers. There are also several epidemiological studies that demonstrated a statistically significant association between increasing mtDNA content in peripheral blood and increased risk of breast cancer(21) as well as other malignancies including Non-Hodgkin lymphoma(22), lung cancer(23), pancreatic cancer(24), and colorectal cancer (25). One study has even found no association between mtDNA content and gastric cancer (26). Furthermore, gender seems to play an important role in mtDNA as males have been confirmed to exhibit lower levels of mtDNA than women (8, 15, 16). No study to date has evaluated the association between constitutive mtDNA content in peripheral blood lymphocytes and risk of bladder cancer. Thus, we performed a study to test our hypothesis that individuals with lower mtDNA content are at increased risk of bladder cancer.

In addition to mtDNA content, the D-loop region in mtDNA is highly polymorphic and several polymorphisms have been investigated and associated with the development of a

variety of solid tumors (27–29). Numerous genetic defects are involved in the initiation and progression of bladder cancer. Moreover, Wada et al. identified mutations in mtDNA D-loop region with the most frequent mutations noted in the poly(C) mononucleotide repeat located at positions 303 to 309 (30). Unfavorable polymorphisms in mtDNA may contribute to increased susceptability in mtDNA damage, lead to decreased mtDNA content which may lead to increased bladder carcinogenesis. The association between mtDNA polymorphisms and mtDNA content in modulating bladder cancer risk has yet to be determined. Therefore, the second objective of our study was to provide proof-of-principle evidence within the context of the current case-control study of bladder cancer for the hypothesis that unfavorable mtDNA polymorphisms are jointly associated with low mtDNA content which are significantly associated with bladder cancer risk.

MATERIALS AND METHODS

Patient Population and Data Collection

In total, 926 bladder cancer (BC) patients with histologically confirmed non-variant urothelial carcinoma were selected for inclusion in the study. Patients with a long history (>1 year) of BC before referral to MD Anderson or Baylor College of Medicine or with a prior medical history of recurrence were excluded. There were no age, gender, ethnicity or cancer stage restrictions on recruitment. 926 healthy control subjects without a history of cancer except nonmelanoma skin cancer and frequency matched to cases by age, gender, and ethnicity were identified and recruited from the Kelsey Seybold clinic (8). After written informed consent was obtained, all study participants completed a 45-minute in-person interview that was administered by MD Anderson Cancer Center staff interviewers. The interview elicited information on demographics, smoking history, family history of cancer, occupational history and exposures, and medical history. At the conclusion of the interview, a 40-mL blood sample was drawn into coded heparinized tubes and delivered to the laboratory for analysis. This analysis was restricted to white subjects because of small sample sizes of subjects of other ethnicities. All patients provided written informed consent and the study protocol has been approved by the MD Anderson Cancer Center institutional review board.

Smoking status and pack-years of smoking were defined as such. A never smoker was defined as a person who had never smoked or smoked fewer than 100 cigarettes in his or her lifetime. A former smoker was defined as a person who had stopped smoking at least 1 year before the diagnosis of cancer (for case patients) or 1 year before the interview (for control subjects). A current smoker was someone who continued smoking or who had stopped smoking less than 1 year before the diagnosis of cancer (case patients) or before the interview (control subjects). The number of pack-years was calculated as the average number of cigarettes smoked per day divided by 20 cigarettes and then multiplied by smoking years.

Determination of mtDNA Content by Real-Time Quantitative Polymerase Chain Reaction

Genomic DNA was extracted from whole blood for all the samples by use of QIAamp DNA Mini kits (Qiagen, Valencia, CA). Relative mtDNA content was measured by a quantitative

real-time polymerase chain reaction (PCR)-based method as previously described (8, 31, 32). In brief, two pairs of primers were designed and used in the two steps of relative quantification for mtDNA content. One primer pair was used for the amplification of the *MT-ND1* gene in mtDNA. The primer sequences were as follows: forward primer (ND1-F), 5′-CCCTAAAACCCGCCACATCT-3′; reverse primer (ND1-R), 5′-GAGCGATGGTGAGAGCTAAGGT-3′. Another primer pair was used for the amplification of the single-copy nuclear gene human globulin (HGB). The primer sequences were as follows: forward primer (HGB-1), 5′-GTGCACCTGACTCCTGAGGAGA-3′; reverse primer (HGB-2), 5′-CCTTGATACCAACCTGCCCAG-3′. In the first step, the ratio of mtDNA content to HGB content was determined for each sample from standard curves. This ratio is proportional to the mtDNA content in each cell. The ratio for each sample was then normalized to a calibrator DNA in order to standardize between different runs. The calibrator DNA is a genomic DNA sample from a healthy control subject to be used for comparison of results of different independent assays. The PCR mixture in a total volume of 14 µL contained 1× SYBR Green Mastermix (Applied Biosystems; Foster City, CA), 215 nM ND1-R (or HGB-1) primer, 215 nM ND1-F (or HGB-2) primer, and 4 ng of genomic DNA. The thermal cycling conditions for the mtDNA (*MT-ND1* gene) amplification were 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute; and for the HGB amplification were 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, and 56°C for 1 minute. All samples were assayed in duplicate on a 384-well plate with an Applied Biosystems 7900 Sequence Detection System. The PCRs for mtDNA and HGB were always performed on separate 384-well plates with the same samples in the same well positions to avoid possible position effect. A standard curve of a diluted reference DNA, one negative control, and one calibrator DNA were included in each run. For each standard curve, one reference DNA sample was serially diluted 1:2 to produce a seven-point standard curve between 0.3125 and 20 ng of DNA. The R^2 for each standard curve was 0.99 or greater. Standard deviations for the cycle of threshold (Ct) value were accepted at 0.25. Otherwise, the test was repeated. To further assess intra-assay variation, we assayed nine blood DNA samples from healthy control subjects three times on the same day. To further evaluate interassay variation, we evaluated the same blood DNA samples from the nine control subjects on different days. All the laboratory personnel performing the experiments described above were blinded to the the case–control status of the DNA samples.

mtDNA Genotyping

Genomic DNA was extracted from peripheral blood samples from 803 control subjects and 803 patients diagnosed with bladder cancer using the method described above. 63 mtDNA SNPs were selected for genotyping. These mtDNA SNPSs were genotyped previously from the iSelect platform. All of the patients' genotypes were called and exported using BeadStudio software (Illumina). The average call rate for the SNP array was 99.7%. All genotyping experiments were carried out according to the standard protocol provided by Illumina Inc. with BeadStudio software. [20]

Statistical Analysis

The Pearson χ^2 test was used to examine the differences in the distribution of case patients and control subjects in terms of sex and smoking status. Rank sum test was used to test for

differences in age, pack-years of smoking, and mtDNA content as continuous variables. To assess the association between mtDNA content and the risk of bladder cancer, data were dichotomized by the use of the median from the distribution of the mtDNA content in control subjects. To assess the dose–response trend, we categorized the mtDNA content using the quartile distribution of the mtDNA content in control subjects. A trend test was performed to test for a linear trend in the odds ratios (ORs) by the quartile cutoff points in control subjects. Unconditional multivariable logistic regression analysis was performed to estimate the odds ratio and 95% confidence interval, adjusting for age, sex and smoking status.

The effects of genotypes of SNPs on bladder cancer risks were estimated as odds ratios and 95% confidence intervals (95% CI) using unconditional multivariate logistic regression under the dominant models of inheritance adjusted for age, gender, and smoking status, where appropriate. The correlation was tested between mtDNA content and each mtDNA SNP in the case and control subjects using Spearman's and Kendall's correlations. The cumulative effects of mtDNA SNPs that showed significant main effects with risk of bladder cancer were assessed by summing the number of unfavorable genotypes (i.e. genotypes associated with increased risk) in each subject and dividing the subjects into two groups according to the median distribution of their risks. The joint effect and interaction analysis was used for the cumulative effects of mtDNA SNPs and mtDNA content. All statistical analyses were two-sided. All statistical analyses were performed with the Stata 10.0 statistical software package (Stata Corp., College Station, TX).

RESULTS

Risk Estimates for Bladder Cancer

The characteristics of the 926 cases and 926 controls are shown in Table 1. While there was no significant difference in age between the cohorts (p=0.7328) and gender, bladder cancer patients were significantly more likely to ever smokers (73.2% vs 56.3%, p<0.001) with increased mean pack-years of smoking (42.2 v 31.2 pack-years, p<0.001).

mtDNA content were significantly different between cases and controls across age and sex subgroups (Table 2). The median mtDNA content was significantly lower among cases versus controls (0.98 vs. 1.04, p<0.001), respectively. While never smokers were found to not have significantly different mtDNA content between cases and controls (1.02 vs. 1.01, p=0.840), ever smokers with bladder cancer had significantly reduced mtDNA content than ever smokers in the control group (0.97 vs. 1.05, p<0.001).

The risk of bladder cancer according to mtDNA content is depicted in Table 3. After dichotomization at the 50th percentile value (or median) of mtDNA content among the control group, individuals with low mtDNA content were at a statistically significant increased risk of bladder cancer (adjusted OR=1.37, 95%CI= 1.13 to 1.66). This was observed for mtDNA content according to quartiles among the control group where individuals with low mtDNA content (1st quartile) had a statistically significant increased risk of bladder cancer (OR=1.63, 95%CI= 1.24 to 2.15) with a significant dose-response trend (p for trend <0.001).

We also performed stratified analyses by host characteristics and found age>65 years (OR 95% CI: 1.56, 1.20–2.02, p<0.001), male sex (OR 95% CI: 1.37, 1.12–1.69, p<0.002) and ever smoking history (OR 95% CI: 1.62, 1.29–2.04, p<0.001) were all significantly associated with low mtDNA content and increased risk of bladder cancer (Table 4). Moreover, we did not observe a significant interaction between lower mtDNA content and smoking history with increased risk of bladder cancer. We observed similareffect sizes and trends for male and female (Supplemental Table).

Detemination of mtDNA Alleles Associated with Bladder Cancer Risk

In the case group, only variant genotype of mitoc15834t was significantly associated with increased mtDNA content (p=0.0372) (Table 5). There were several variant genotypes (mitog15929a, mitoa11813g, mitoa14906g, mitoa4918g, mitot10464c) significantly associated with increased mtDNA content in the control group. There were two notable mtDNA alleles which achieved significance for risk of bladder cancer: mitot10464c (OR=1.39, 95%CI: 1.00–1.93, p=0.048) and mitoa4918g (OR=1.40, 95% CI: 1.00–1.95, p=0.049). mitot10464c was significantly correlated with increased mtDNA content in the control group (r=0.1023, p=0.0152), had borderline significance for decreased mtDNA content in the case group (r=−0.0534, p=0.0941) and significantly associated with increased risk of bladder cancer. There was a significant interaction between mitoa4918g and low mtDNA content (p for interaction = 0.028). No other significant interactions were observed.

When we assessed the joint effect of mtDNA content and unfavorable mtDNA polymorphisms on risk, we observed a significant increase of risk for a low mtDNA content with 0–1 unfavorable genotypes (OR = 1.34, 95% CI, 1.06–1.68) and low mtDNA content with most number of unfavorable genotypes (OR = 2.50, 95% CI: 1.60–3.94), compared with 0–1 unfavorable mtDNA polymorphisms and a high mtDNA content (Table 6).

DISCUSSION

Despite multimodality treatments for bladder cancer, there remains a need for improved early detection and patient selection to optimize outcomes. Several clinicopathological characteristics influence the course of treatments for bladder cancer, however, there is a need for the development of improved biomarkers (33). Mitochondrial genome deletion may serve as a surrogate predictive biomarker for bladder cancer biopsy. There is evidence supporting that notion as, recently, a mutation in mtDNA has been used to help diagnose prostate cancer in patients with negative prostate biopsy (34).Our study identified low mtDNA content to be significantly associated with increased risk of bladder cancer and mtDNA content may aid in the detection of individuals at risk for bladder cancer. Furthermore, we identified several mtDNA SNPs associated with mtDNA content, two new susceptibility mtDNA SNPs associated with bladder cancer risk and a significant interaction noted between mitoa4918g and low mtDNA content.

Given the essential involvement of mitochondria in many important physiological processes, including metabolism, signaling, apoptosis, cell cycle, and differentiation, it is not surprising that alterations in mtDNA content can contribute to the development of various cancers (35). The mitochondrial genome encompasses thousands of copies of mtDNA which retains the

13 most important genes that control oxidative phophorylation (35). A shift from oxidative to more glycolytic-like metabolism is a hallmark finding in many cancer cells (35). Moreover, a decrease in mtDNA content may also promote cancer cells to become resistant to apoptosis which may further lead to the induction of many carcinogenic pathways (36). However, different types of cancer undergo different bioenergetic alterations, leading some to be more glycolytic and others to become more oxidative, which may explain increased mtDNA content associated with certain malignancies as well [23, 24].

In the present study of bladder cancer, we found lower mtDNA content was associated with a 1.37-fold increased risk of bladder cancer when mtDNA content was dichotomized by median cutoff in the controls. To the best of our knowledge, this is the first molecular epidemiological study to evaluate mtDNA content in peripheral blood lymphocytes as a susceptibility biomarker for bladder cancer. These findings corroborate prior studies in other cancers which identified similar decreases in mtDNA content associated with cancer risk (8, 15–20). Furthermore, our study demonstrated a significant dose-incremental increased risk of bladder cancer according to mtDNA depletion. As cancer cells shift from an oxidative to more glycolytic metabolism they may induce several carcinogenic pathways including the PI3K–PTEN–AKT signal transduction pathway limiting apoptosis and increase cancer cell survival (37). Thus, a decrease in mtDNA content suggests a shift to a more glycolytic state and increased susceptibility to bladder cancer initiation and propagation. The use of mtDNAs extracted from human peripheral leukocytes or whole blood (only leukocytes in whole blood contain mtDNA) has been previously proven as a robust method for demonstrating the heritability and associated risks for other malignancies (8, 15). Furthermore, the use of mtDNA extracted from lymphocytes uses a reproducible method which moving forward will be helpful to compare data for this and other malignancies.

Smoking history is a well-known risk factor for many malignancies with current smokers having a three-fold increased risk of bladder cancer than non-smokers (38). After controlling for age and sex, we identified smoking history to be significantly associated with decreased mtDNA content and increased risk of bladder cancer. However, further analyses failed to identify a significant interaction between smoking history and low mtDNA content with risk of bladder cancer. Prior studies in renal cell carcinoma indicated that an increased mtDNA content was associated with smoking history (8) leading to the assumption that smokers have an increased need for more copies of mtDNA which are damaged by smoking. Our data suggest the possibility that the decreased ability to produce extra copies of mtDNA due to damage from smoking may further increase the risk of bladder cancer. Thus, while we failed to observe a significant interaction, the present study makes a compelling assumption that decreased mtDNA content is an important biomarker for bladder cancer which may be exacerbated by the carcinogenic risks associated with smoking.

Men had significantly lower mtDNA content than women among both case patients and control subjects. Bladder cancer is the fourth most common cancer among men and is no longer among the top ten cancers diagnosed among women in the US (1). However, female gender has been associated with inferior outcomes and poor response to treatments when disease develops (39). While the impact of gender on the staging and prognosis have attempted to explain this discordance through differences in access to care versus tumor

biology (40), our findings support genetic determinants may predispose to gender-specific risk of bladder cancer. The role of sex-steroids and bladder cancer have suggested increased risk to bladder cancer among men with polymorphisms leading to a more aggressive phenotype (41). Our findings suggest mtDNA may also be an important driver for bladder cancer, however, the precise mechanisms which determine mtDNA content and how gender influences mtDNA content remain to be elucidated.

We report herein two new susceptibility mtDNA SNPs associated with bladder cancer risk. The biological implications of these SNPs remain to be defined and warrant further laboratory investigation. mtDNA SNPs have been previously implicated in other malignancies including malignant melanoma and renal cell carcinoma where alleles in the displacement loop (D-loop) mtDNA were associated with an increased cancer risk (42, 43). Moreover, examination of cancers of the bladder, head and neck, and lung primary tumors have previously revealed a high frequency of mtDNA mutations (27). The authors found mtDNA variant alleles to be dominant in tumor cells, readily detectable and 19 to 220 times as abundant as mutated nuclear p53 DNA. Taking our study results with mtDNA clonal nature and mtDNA content, mtDNA mutations may provide a powerful molecular marker for noninvasive detection of bladder cancer.

We observed an increased risk of bladder cancer according to low mtDNA content and unfavorable mtDNA genotypes with a significant interaction noted between mitoa4918g and low mtDNA content. We are the first to report these findings according to underlying risk of bladder cancer. A prior study identified variability in the mtDNA D-loop control region (303 polyC or 16184 polyC) in 76.9% of patients suspected of having bladder cancer (44). The noncoding mtDNA D-loop control region may effect mtDNA production and represents a hot spot for somatic mutations (45). We were unable to identify the functional significance of mitoa4918g or any of the other unfavorable genotypes, however, this represents an area of research needed to discern the precise role of these interactions in the early recognition of bladder carcinogenesis.

Our findings must be interpreted in the context of our study design and had a few limitations. First, although we found low mtDNA content in peripheral blood leukocytes to be associated with increased risk of bladder cancer, the cause-effect relationship between mtDNA content as a surrogate marker and cancer remains to be determined. In our current study, we recruited newly diagnosed bladder cancer cases and collected blood samples before treatment, which should minimize the potential impact of treatment on mtDNA content. Second, the study is restricted to Caucasion populations. Validation of the finding in other ethnicity is warranted. Third, we previously published the utility and heritability of mtDNA extracted from peripheral blood leukocytes (8, 15, 16, 18), however, differences of mtDNA content among leukocyte subpopulations exists which may warrant further studies among different subpopulations of leukocytes to discern this variability. Finally, while we provide further evidence to suggest the importance of mtDNA content and identify significant mtDNA polymorphisms with an interaction noted between mitoa4918g and low mtDNA content, future prospective validation is warranted to confirm our findings.

In summary, we found low mtDNA content was significantly associated with increased risk of bladder cancer. Furthermore, we identified two new susceptibility mtDNA alleles associated with bladder cancer risk and a significant interaction noted between unfavorable genotype mitoa4918g and low mtDNA content. These findings warrant further validation in order to better identify patients most at risk for bladder cancer.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

REFERENCES

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. [PubMed: 24399786]

2. Zehnder P, Studer UE, Skinner EC, Thalmann GN, Miranda G, Roth B, et al. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU Int. 112:E51–E58. [PubMed: 23795798]

3. Xylinas E, Kluth LA, Rieken M, Karakiewicz PI, Lotan Y, Shariat SF. Urine markers for detection and surveillance of bladder cancer. Urologic oncology. 2014; 32:222–229. [PubMed: 24054865]

4. Lotan Y, Elias K, Svatek RS, Bagrodia A, Nuss G, Moran B, et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. The Journal of urology. 2009; 182:52–57. discussion 8. [PubMed: 19450825]

5. Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 2010; 105:300–308. [PubMed: 19912200]

6. Puente D, Malats N, Cecchini L, Tardon A, Garcia-Closas R, Serra C, et al. Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. Eur Urol. 2003; 43:53–62. [PubMed: 12507544]

7. Fernandez-Silva P, Enriquez JA, Montoya J. Replication and transcription of mammalian mitochondrial DNA. Exp Physiol. 2003; 88:41–56. [PubMed: 12525854]

8. Xing J, Chen M, Wood CG, Lin J, Spitz MR, Ma J, et al. Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. Journal of the National Cancer Institute. 2008; 100:1104–1112. [PubMed: 18664653]

9. Gahan ME, Miller F, Lewin SR, Cherry CL, Hoy JF, Mijch A, et al. Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time polymerase chain reaction. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2001; 22:241–247. [PubMed: 11564588]

10. Cavelier L, Jazin EE, Eriksson I, Prince J, Bave U, Oreland L, et al. Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Genomics. 1995; 29:217–224. [PubMed: 8530074]

11. Tiao MM, Lin TK, Kuo FY, Huang CC, Du YY, Chen CL, et al. Early stage of biliary atresia is associated with significant changes in 8-hydroxydeoxyguanosine and mitochondrial copy number. Journal of pediatric gastroenterology and nutrition. 2007; 45:329–334. [PubMed: 17873745]

12. Gemma C, Sookoian S, Alvarinas J, Garcia SI, Quintana L, Kanevsky D, et al. Mitochondrial DNA depletion in small- and large-for-gestational-age newborns. Obesity. 2006; 14:2193–2199. [PubMed: 17189546]

13. Capps GJ, Samuels DC, Chinnery PF. A model of the nuclear control of mitochondrial DNA replication. Journal of theoretical biology. 2003; 221:565–583. [PubMed: 12713941]

14. Moraes CT. What regulates mitochondrial DNA copy number in animal cells? Trends in genetics : TIG. 2001; 17:199–205. [PubMed: 11275325]

15. Xu E, Sun W, Gu J, Chow WH, Ajani JA, Wu X. Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma. Carcinogenesis. 34:2521–2524. [PubMed: 23803692]

16. Xie H, Lev D, Gong Y, Wang S, Pollock RE, Wu X, et al. Reduced mitochondrial DNA copy number in peripheral blood leukocytes increases the risk of soft tissue sarcoma. Carcinogenesis. 34:1039–1043. [PubMed: 23349016]

17. Wang Y, Liu VW, Xue WC, Cheung AN, Ngan HY. Association of decreased mitochondrial DNA content with ovarian cancer progression. Br J Cancer. 2006; 95:1087–1091. [PubMed: 17047655]

18. Wu CW, Yin PH, Hung WY, Li AF, Li SH, Chi CW, et al. Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer. 2005; 44:19–28. [PubMed: 15892105]

19. Lee HC, Li SH, Lin JC, Wu CC, Yeh DC, Wei YH. Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res. 2004; 547:71–78. [PubMed: 15013701]

20. Tseng LM, Yin PH, Chi CW, Hsu CY, Wu CW, Lee LM, et al. Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer. 2006; 45:629–638. [PubMed: 16568452]

21. Shen J, Platek M, Mahasneh A, Ambrosone CB, Zhao H. Mitochondrial copy number and risk of breast cancer: a pilot study. Mitochondrion. 2010; 10:62–68. [PubMed: 19788937]

22. Lan Q, Lim U, Liu CS, Weinstein SJ, Chanock S, Bonner MR, et al. A prospective study of mitochondrial DNA copy number and risk of non-Hodgkin lymphoma. Blood. 2008; 112:4247–4249. [PubMed: 18711000]

23. Hosgood HD 3rd, Liu CS, Rothman N, Weinstein SJ, Bonner MR, Shen M, et al. Mitochondrial DNA copy number and lung cancer risk in a prospective cohort study. Carcinogenesis. 2010; 31:847–849. [PubMed: 20176654]

24. Lynch SM, Weinstein SJ, Virtamo J, Lan Q, Liu CS, Cheng WL, et al. Mitochondrial DNA copy number and pancreatic cancer in the alpha-tocopherol beta-carotene cancer prevention study. Cancer prevention research (Philadelphia, Pa). 2011; 4:1912–1919.

25. Qu F, Liu X, Zhou F, Yang H, Bao G, He X, et al. Association between mitochondrial DNA content in leukocytes and colorectal cancer risk: a case-control analysis. Cancer. 2011; 117:3148–3155. [PubMed: 21246538]

26. Liao LM, Baccarelli A, Shu XO, Gao YT, Ji BT, Yang G, et al. Mitochondrial DNA copy number and risk of gastric cancer: a report from the Shanghai Women's Health Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2011; 20:1944–1949.

27. Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science (New York, NY). 2000; 287:2017–2019.

28. Suzuki M, Toyooka S, Miyajima K, Iizasa T, Fujisawa T, Bekele NB, et al. Alterations in the mitochondrial displacement loop in lung cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9:5636–5641. [PubMed: 14654546]

29. Lievre A, Chapusot C, Bouvier AM, Zinzindohoue F, Piard F, Roignot P, et al. Clinical value of mitochondrial mutations in colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23:3517–3525. [PubMed: 15908662]

30. Wada T, Tanji N, Ozawa A, Wang J, Shimamoto K, Sakayama K, et al. Mitochondrial DNA mutations and 8-hydroxy-2'-deoxyguanosine Content in Japanese patients with urinary bladder and renal cancers. Anticancer research. 2006; 26:3403–3408. [PubMed: 17094459]

31. Kaaman M, Sparks LM, van Harmelen V, Smith SR, Sjolin E, Dahlman I, et al. Strong association between mitochondrial DNA copy number and lipogenesis in human white adipose tissue. Diabetologia. 2007; 50:2526–2533. [PubMed: 17879081]

32. Santos TA, El Shourbagy S, St John JC. Mitochondrial content reflects oocyte variability and fertilization outcome. Fertil Steril. 2006; 85:584–591. [PubMed: 16500323]

33. Mossanen M, Lee F, Cheng H, Harris W, Shenoi J, Zhao S, et al. Nonresponse to Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. Clin Genitourin Cancer.

34. Maki J, Robinson K, Reguly B, Alexander J, Wittock R, Aguirre A, et al. Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens. American journal of clinical pathology. 2008; 129:57–66. [PubMed: 18089489]

35. Wallace DC. Mitochondria and cancer. Nature reviews Cancer. 2012; 12:685–698.

36. Martinez-Caballero S, Dejean LM, Kinnally MS, Oh KJ, Mannella CA, Kinnally KW. Assembly of the mitochondrial apoptosis-induced channel, MAC. The Journal of biological chemistry. 2009; 284:12235–12245. [PubMed: 19261612]

37. Peixoto PM, Ryu SY, Bombrun A, Antonsson B, Kinnally KW. MAC inhibitors suppress mitochondrial apoptosis. The Biochemical journal. 2009; 423:381–387. [PubMed: 19691447]

38. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA : the journal of the American Medical Association. 2011; 306:737–745.

39. Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, et al. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology. 83:863–868. [PubMed: 24485993]

40. Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Roupret M, et al. Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. Eur Urol.

41. Gakis G, Stenzl A. Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity. World J Urol. 31:1059–1064. [PubMed: 23397433]

42. Zhang W, Wang W, Jia Z. Single nucleotide polymorphisms in the mitochondrial displacement loop region modifies malignant melanoma: a study in Chinese Han population. Mitochondrial DNA. 2014

43. Bai Y, Guo Z, Xu J, Liu S, Zhang J, Cui L, et al. Single nucleotide polymorphisms in the D-loop region of mitochondrial DNA is associated with renal cell carcinoma outcome. Mitochondrial DNA. 2013

44. Yoo JH, Suh B, Park TS, Shin MG, Choi YD, Lee CH, et al. Analysis of fluorescence in situ hybridization, mtDNA quantification, and mtDNA sequence for the detection of early bladder cancer. Cancer Genet Cytogenet. 198:107–117. [PubMed: 20362225]

45. Jazin EE, Cavelier L, Eriksson I, Oreland L, Gyllensten U. Human brain contains high levels of heteroplasmy in the noncoding regions of mitochondrial DNA. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93:12382–12387. [PubMed: 8901590]

Table 1

Distribution of selected characteristics of case patients with bladder cancer and healthy control subjects

Variables	Cases (n=926)	Controls (n=926)	P value[b]
Age (years), mean (SD)	65.2 (11.4)	63.3 (11.1)	0.7328
Sex, No. (%)			
Male	738 (79.7)	738 (79.7)	1.000
Female	188 (20.3)	188 (20.3)	
Smoking, No. (%)			
Never	248 (26.8)	405 (43.7)	<0.001
Former	436 (47.1)	442 (47.7)	
Current	242 (26.1)	79 (8.5)	
Ever	678 (73.2)	521 (56.3)	<0.001
Mean pack-years of smoking(SD)[a]	42.2 (30.0)	31.2 (28.3)	<0.001

mtDNA= mitochondrial DNA

[a]Pack-year was assessed for ever smokers only

[b]Differences in the distribution of sex and smoking status were tested with the Pearson χ^2 test.
Student t test was used to test for differences in age and pack-years of smoking. All statistical tests were two-sided.

Table 2

mtDNA copy number by host characteristics of case patients with bladder cancer and control subjects

Variables	Cases			Controls		
	No. of patients	mtDNA, median(range)	No. of patients	mtDNA, median(range)	*P* value
mtDNA copy number						
Median (range)	926	0.98 (0.38– 3.26)	926	1.04 (0.47– 5.09)	<0.001
Age (years)						
65	463	0.99(0.38–3.26)	496	1.03 (0.48–5.09)	0.005
>65	463	0.97(0.40–3.24)	430	1.04 (0.47–3.86)	0.002
Sex						
Male	738	0.97(0.38–3.26)	738	1.02 (0.47–5.09)	<0.001
Female	188	1.04 (0.62–2.70)	188	1.08 (0.56–2.67)	0.058
Smoking status[a]						
Never	248	1.02 (0.44–2.54)	405	1.01 (0.47–3.91)	0.840
Ever	678	0.97 (0.38–3.26)	521	1.05 (0.47–5.09)	<0.001

mtDNA= mitochondrial DNA

Log rank sum was used to test for differences in mtDNA copy number, age sex and smoking status. All statistical tests were two-sided.

[a]Smoking status: individuals who had smoked .100 cigarettes in their life time were defined as ever-smokers; others were never-smokers. Smokers included current smokers and former smokers. Individuals who had quit smoking at least 1 year before diagnosis were categorized as former smokers.

Table 3

Risk of bladder cancer as estimated by mtDNA copy number

mtDNA copy number	Cases No. (%)	Control No. (%)	Adjusted OR[a] (95% CI)	P value
By median[b]				
>1.04	385 (41.6)	463 (50.0)	1(reference)	
1.04	541 (58.4)	463 (50.0)	1.37 (1.13 to 1.66)	0.001
By quartile[c]				
>1.24	167 (18.0)	231 (25.0)	1(reference)	
1.04–1.24	218 (23.5)	232 (25.0)	1.23 (0.93 to 1.63)	0.153
0.88–1.04	252 (27.2)	232 (25.0)	1.42 (1.08 to 1.87)	0.013
0.88	289 (31.2)	231 (25.0)	1.63 (1.24 to 2.15)	<0.001
P for trend				<0.001

mt DNA= mitochondrial DNA; OR= odds ratio; CI= confidence interval

[a]Odds ratios were adjusted by age, sex and smoking status. The trend in odds ratios was tested by use of the test for linear trend. All statistical tests were two-sided.

[b]Median is based on levels in control subjects.

[c]Quartile is based on levels in control subjects

Table 4

Association of bladder cancer with mtDNA copy number stratified by selected host characteristics

Host characeristics	Cases No. (%)	Control No. (%)	Adjusted OR[a] (95%CI)	*P* value
Age (years)				
Age 65				
>1.04	192(40.51)	260(49.15)	1 (reference)	
1.04	282(59.49)	269(50.85)	1.27 (0.98 to 1.66)	0.073
Age>65				
>1.04	224(40.58)	230(51.00)	1 (reference)	
1.04	328(59.42)	221(49.00)	1.56 (1.20 to 2.02)	<0.001
Sex				
Male				
>1.04	320(38.69)	356(47.21)	1 (reference)	
1.04	507(61.31)	398(52.79)	1.37 (1.12 to 1.69)	0.002
Female				
>1.04	96(48.24)	134(59.29)	1 (reference)	
1.04	103(51.76)	92(40.71)	1.48 (0.99 to 2.21)	0.058
Smoking status[b]				
Never smoking				
>1.04	123(45.22)	211(48.17)	1 (reference)	
1.04	149(54.78)	227(51.83)	1.09 (0.80 to 1.48)	0.580
Ever smoking				
>1.04	293(38.86)	279(51.48)	1 (reference)	
1.04	461(61.14)	263(48.52)	1.62 (1.29 to 2.04)	<0.001

mt DNA= mitochondrial DNA; OR= odds ratio; CI= confidence interval

[a]Age: adjusted for sex and smoking status; Sex: adjusted for age and smoking status; Smoking status: adjusted for age and sex

[b]Smoking status: individuals who had smoked .100 cigarettes in their lifetime were defined as ever-smokers; others were never-smokers. Smokers included current smokers and former smokers. Individuals who had quit smoking at least 1 year before diagnosis were categorized as former smokers.

Table 5

Determination of mtDNA genotypes and copy number among subset of case patients with bladder cancer and healthy control subjects

Genotypes	Association of mtDNA SNPs with mtDNA content						Association of mtDNA SNPs with Bladder Cancer Risk	
	No. Non Variant mtDNA	Non Variant mtDNA, median (range)	No. Variant mtDNA	Variant mtDNA, median (range)	Linear Coefficient	P value[a]	Adjusted OR[b] (95% CI)	P value
Cases (n= 806)								
mitoc15834t	767	0.96 (0.40–3.26)	16	1.16 (0.53–2.44)	0.1533	0.0372	1.12 (0.54–2.34)	0.7621
mitog16392a	739	0.97 (0.40–3.26)	15	1.02 (0.65–2.75)	0.1302	0.0872	1.00 (0.47–2.15)	0.9916
mitot10464c[c]	694	0.97 (0.40–3.26)	97	0.95 (0.60–1.65)	−0.0534	0.0941	1.39 (1.00–1.93)	0.0483
Controls (n=787)								
mitog15929a	669	1.01 (0.47–3.91)	76	1.12 (0.65–3.54)	0.1273	0.0022	1.38 (0.99–1.92)	0.0571
mitoa11813g	733	1.01 (0.47–3.91)	62	1.12 (0.65–3.54)	0.1275	0.0054	1.11 (0.77–1.61)	0.5706
mitoa14906g	707	1.01 (0.47–3.91)	74	1.12 (0.65–3.54)	0.1068	0.0119	1.36 (0.98–1.90)	0.0662
mitoa4918g[c]	722	1.01 (0.47–3.91)	72	1.12 (0.65–3.54)	0.1055	0.0140	1.40 (1.00–1.95)	0.0492
mitot10464c[c]	718	1.01 (0.47–3.91)	75	1.11 (0.65–3.54)	0.1023	0.0152	1.39 (1.00–1.94)	0.0482

mt DNA= mitochondrial DNA; OR= odds ratio; CI= confidence interval

[a] Derived from linear regression analysis adjusted by age, sex and smoking status.

[b] Odds ratios were adjusted by age, sex and smoking status. The trend in odds ratios was tested by use of the test for linear trend. All statistical tests were two-sided.

[c] Joint analyses: mitot10464c and mtDNA content (p for interaction = 0.0570); mitoa4918g and mtDNA content (p for interaction = 0.028).

Table 6

Joint effect analyses of mtDNA copy number and unfavorable mtDNA polymorphisms associated with bladder cancer risk

No. Unfavorable polymorphisms, mtDNA copy number based on median[*]	Cases No. (%)	Control No. (%)	Adjusted OR[a] (95% CI)	P value
0–1, high	252 (34.6)	319 (42.8)	1(reference)	
0–1, low	357 (49.0)	336 (45.1)	1.34 (1.06–1.68)	0.0129
2–4, high	48 (6.6)	55 (7.4)	1.16 (0.80–1.78)	0.5119
2–4, low	72 (9.9)	35 (4.7)	2.50 (1.60–3.94)	<0.001
P for interaction				0.1280

[*]Unfavorable genotypes: mitot9900c, mitog5047a, mitog752a, mitot12415c, mitog5461a, mitoa4918g